Lucentis improves vision for DME sufferers
This article was originally published in Scrip
Executive Summary
Encouraging Phase III results raise hopes for an additional ophthalmic indication for Lucentis. Results presented at the recent American Diabetes Association meeting reveal that Roche's Lucentis (ranibizumab) significantly improves visual acuity among patients with diabetic macular edema (DME). If approved by the FDA, this would give Lucentis a third indication within the US ophthalmic market.
You may also be interested in...
Extended hold on Arikace dogs Insmed and delays verdict on liposomes in CF
The FDA is continuing its clinical hold on Arikace, the clinical hold placed in August on Phase III trials of Arikace, a hotly-tipped cystic fibrosis candidate, until second species carcinogenicity data is generated. This will significantly delay the development of this keenly awaited antibiotic which is spearheading new liposomal technology.
J&J's Remicade poised to dominate paediatric ulcerative colitis market
Paediatric patients in Canada will become the first to have access to Remicade (infliximab) for treating moderately to severely active ulcerative colitis, following Health Canada’s approval of the drug for this indication. This decision is likely to pave the way for similar indication extensions for children in other markets.